At any rate, none of the NAEs and 2-MAGs that we found to be elevated by olanzapine are capable of activating CB1, and hence producing dysmetabolic effects in the context of obesity, with the exception of the endocannabinoid 2-AG. This evidence concerns the gene CNR1 and obesity disorder.